Target Name: CYBB
NCBI ID: G1536
Review Report on CYBB Target / Biomarker Content of Review Report on CYBB Target / Biomarker
CYBB
Other Name(s): p22 phagocyte B-cytochrome | cytochrome b558 subunit beta | Cytochrome b(558) subunit beta | Cytochrome b-245 beta chain | Cytochrome b558 subunit beta | AMCBX2 | cytochrome b-245 beta polypeptide | gp91-1 | IMD34 | CY24B_HUMAN | heme-binding membrane glycoprotein gp91phox | GP91-1 | neutrophil cytochrome b 91 kDa polypeptide | CGDX | gp91-phox | Cytochrome b-245 heavy chain | NADPH oxidase 2 | NOX-2 | p91-PHOX | Superoxide-generating NADPH oxidase heavy chain subunit | cytochrome b-245 beta chain | CGD91-phox | GP91-PHOX | NOX2 | superoxide-generating NADPH oxidase heavy chain subunit | CGD | Heme-binding membrane glycoprotein gp91phox | GP91PHOX | cytochrome b(558) subunit beta | Neutrophil cytochrome b 91 kDa polypeptide

Understanding CYBB: The Neurotoxin-Metabolizing Enzyme

CYBB, or cytochrome P450 enzyme B, is a protein that is expressed in the cells of the nervous system and play a crucial role in the metabolism of a variety of compounds, including drugs. It is a member of the superfamily of cytochrome P450 enzymes, which are a group of proteins that are involved in the detoxification and metabolism of a wide variety of drugs and other compounds.

One of the unique features of CYBB is its location in the nervous system. This makes it an attractive target for researchers because it is typically expressed in high levels in the brain and other nervous system cells, which makes it a good candidate for drug delivery and targeting.

In addition, CYBB is known for its role in the metabolism of many different drugs, including statins, which are used to treat high cholesterol. Many drugs that are used to treat a wide range of diseases and conditions are metabolized by CYBB, which means that they can be either beneficial or harmful depending on how they are metabolized.

Another important aspect of CYBB is its role in the detoxification of drugs. Many drugs can cause harm to the body if they are not properly metabolized, and CYBB is involved in the process of removing these drugs from the body. This can be important for individuals who are taking multiple drugs for different conditions and may be at risk for developing adverse reactions to one or more of them.

Despite its many important functions, CYBB is not without its challenges. One of the biggest challenges is its relatively high expression level, which can make it difficult to reduce to a low level in the body. This can limit its effectiveness as a drug target or biomarker, as it may not be able to provide a reliable response to therapeutic treatments.

Another challenge is the complexity of the CYBB gene. The CYBB gene is located on chromosome 19 and has a highly conserved structure, which makes it difficult to identify and modify. This can make it difficult to develop new drugs or other treatments that specifically target CYBB.

Despite these challenges, CYBB is an important protein that plays a crucial role in the nervous system and the body's response to many different drugs. As research continues to advance, it is likely that new and innovative treatments will be developed that specifically target CYBB and its unique functions.

Protein Name: Cytochrome B-245 Beta Chain

Functions: Critical component of the membrane-bound oxidase of phagocytes that generates superoxide. It is the terminal component of a respiratory chain that transfers single electrons from cytoplasmic NADPH across the plasma membrane to molecular oxygen on the exterior. Also functions as a voltage-gated proton channel that mediates the H(+) currents of resting phagocytes. It participates in the regulation of cellular pH and is blocked by zinc

The "CYBB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYBB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CYBC1 | CYBRD1 | CYC1 | Cyclin | Cyclin A | Cyclin B | Cyclin D | Cyclin D2-CDK4 complex | Cyclin-dependent kinase | Cyclin-dependent kinase inhibitor | Cyclooxygenase (COX) | Cyclophilins | CYCS | CYCSP25 | CYCSP34 | CYCSP38 | CYCSP51 | CYCSP52 | CYCSP53 | CYCSP55 | CYFIP1 | CYFIP2 | CYGB | CYLC1 | CYLC2 | CYLD | CYLD-AS1 | CYMP | CYP11A1 | CYP11B1 | CYP11B2 | CYP17A1 | CYP19A1 | CYP1A1 | CYP1A2 | CYP1B1 | CYP1B1-AS1 | CYP20A1 | CYP21A1P | CYP21A2 | CYP24A1 | CYP26A1 | CYP26B1 | CYP26C1 | CYP27A1 | CYP27B1 | CYP27C1 | CYP2A13 | CYP2A6 | CYP2A7 | CYP2A7P1 | CYP2B6 | CYP2B7P | CYP2C18 | CYP2C19 | CYP2C61P | CYP2C8 | CYP2C9 | CYP2D6 | CYP2D7 | CYP2D8P | CYP2E1 | CYP2F1 | CYP2F2P | CYP2G1P | CYP2J2 | CYP2R1 | CYP2S1 | CYP2T1P | CYP2U1 | CYP2U1-AS1 | CYP2W1 | CYP39A1 | CYP3A4 | CYP3A43 | CYP3A5 | CYP3A51P | CYP3A7 | CYP3A7-CYP3A51P | CYP3AP2 | CYP46A1 | CYP4A11 | CYP4A22 | CYP4B1 | CYP4F11 | CYP4F12 | CYP4F2 | CYP4F22 | CYP4F26P | CYP4F29P | CYP4F3 | CYP4F30P | CYP4F34P | CYP4F35P | CYP4F59P | CYP4F62P | CYP4F8 | CYP4V2 | CYP4X1 | CYP4Z1